These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11311660)

  • 1. Mechanisms of action of flavopiridol.
    Sedlacek HH
    Crit Rev Oncol Hematol; 2001 May; 38(2):139-70. PubMed ID: 11311660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
    Raju U; Nakata E; Mason KA; Ang KK; Milas L
    Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
    Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
    Shapiro GI; Koestner DA; Matranga CB; Rollins BJ
    Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
    Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
    Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
    Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
    Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
    Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
    Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
    Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
    J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
    Shapiro GI
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol.
    Semenov I; Akyuz C; Roginskaya V; Chauhan D; Corey SJ
    Leuk Res; 2002 Mar; 26(3):271-80. PubMed ID: 11792416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.
    Smith V; Raynaud F; Workman P; Kelland LR
    Mol Pharmacol; 2001 Nov; 60(5):885-93. PubMed ID: 11641415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.
    Kaiser A; Nishi K; Gorin FA; Walsh DA; Bradbury EM; Schnier JB
    Arch Biochem Biophys; 2001 Feb; 386(2):179-87. PubMed ID: 11368340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.
    Lee HR; Chang TH; Tebalt MJ; Senderowicz AM; Szabo E
    Int J Oncol; 1999 Jul; 15(1):161-6. PubMed ID: 10375610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.
    Matranga CB; Shapiro GI
    Cancer Res; 2002 Mar; 62(6):1707-17. PubMed ID: 11912144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
    Gojo I; Zhang B; Fenton RG
    Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.